BIAF
bioAffinity Technologies, Inc.
NASDAQ: BIAF · HEALTHCARE · DIAGNOSTICS & RESEARCH
$2.49
+2.26% today
Updated 2026-04-30
Market cap
$10.03M
P/E ratio
—
P/S ratio
1.63x
EPS (TTM)
$-8.66
Dividend yield
—
52W range
$1 – $15
Volume
10.8M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D6.0
Quality
B2.0
Profitability
F6.7
Valuation
B1/9
Piotroski F-Score
Weak
-15.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$6.00
+141.45%
12-Month target
—
—
Intrinsic (DCF)
$5.88
Margin of safety
+83.11%
Price chart
X-Ray snapshot
Strengths
+ 83.11% below intrinsic value
+ Debt/equity 0.08x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -15.62 — distress zone
- Thin margins at -242.00%
- Negative free cash flow $-2.62M
- Revenue declining -27.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $4803.00 | $2.53M | $9.36M | $6.16M | $6.16M |
| Net income | $-8.15M | $-7.94M | $-9.04M | $-14.91M | $-3.14M |
| EPS | — | — | — | — | $-8.66 |
| Free cash flow | $-4.29M | $-6.06M | $-7.34M | $-9.39M | $-2.62M |
| Profit margin | -169,771.25% | -313.47% | -96.56% | -241.96% | -242.00% |
Peer comparison
Smart narrative
bioAffinity Technologies, Inc. trades at $2.49. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -15.62, it sits in the distress. TTM revenue stands at $6.16M. with profit margins at -242.00%. Our DCF model estimates intrinsic value at $5.88.
Frequently asked questions
What is bioAffinity Technologies, Inc.'s stock price?
bioAffinity Technologies, Inc. (BIAF) trades at $2.49.
Is bioAffinity Technologies, Inc. overvalued?
Smart Value Score 26/100 (Grade F, Strong Sell). DCF value $5.88.
What is the price target of bioAffinity Technologies, Inc. (BIAF)?
The analyst target price is $6.00, representing +141.4% upside from the current price of $2.49.
What is the intrinsic value of bioAffinity Technologies, Inc. (BIAF)?
Based on our DCF model, intrinsic value is $5.88, a +83.1% margin of safety versus $2.49.
What is bioAffinity Technologies, Inc.'s revenue?
TTM revenue is $6.16M.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
-15.62 — distress.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.63x
ROE-301.80%
Beta-0.82
50D MA$2.37
200D MA$3.67
Shares out0.00B
Float0.00B
Short ratio—
Avg volume10.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—